Humacyte (HUMA) Expected to Announce Earnings on Friday

Humacyte (NASDAQ:HUMA) is projected to post its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect Humacyte to post earnings of ($0.13) per share and revenue of $1.3490 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Humacyte Stock Up 3.6%

Humacyte stock opened at $0.82 on Thursday. The firm has a market capitalization of $154.12 million, a P/E ratio of -3.58 and a beta of 1.89. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. Humacyte has a twelve month low of $0.70 and a twelve month high of $2.93. The stock’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.29.

Analyst Ratings Changes

Several research firms recently commented on HUMA. Benchmark lowered their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Humacyte in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, March 17th. Finally, UBS Group restated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.14.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently bought and sold shares of HUMA. Marshall Wace LLP boosted its stake in Humacyte by 5,308.2% in the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after acquiring an additional 2,590,394 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Humacyte by 129.5% in the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock valued at $2,528,000 after purchasing an additional 1,485,152 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Humacyte by 33.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after purchasing an additional 738,142 shares during the last quarter. Barclays PLC boosted its position in shares of Humacyte by 298.7% in the 4th quarter. Barclays PLC now owns 729,469 shares of the company’s stock valued at $701,000 after purchasing an additional 546,491 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Humacyte by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock valued at $13,085,000 after purchasing an additional 520,431 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.